[Federal Register Volume 62, Number 80 (Friday, April 25, 1997)]
[Notices]
[Pages 20190-20191]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-10780]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of the Committee: Veterinary Medicine Advisory Committee.
    General Function of the Committee: Reviews and evaluates available 
data concerning the safety and effectiveness of marketed and 
investigational new animal drugs, feeds, and devices for use in the 
treatment and prevention of animal disease and increased animal 
production.
    Date and Time: The meeting will be held on May 13 and 14, 1997, 
8:30 a.m. to 4:30 p.m. Open public hearing portions are scheduled from 
2:30 p.m. to 3:30 p.m. on May 13, 1997, and from 1 p.m. to 2 p.m. on 
May 14, 1997.
    Location: Holiday Inn--Gaithersburg, Goshen Room, Two Montgomery 
Village Ave., Gaithersburg, MD.
    Contact Person: Jacquelyn L. Pace, Center for Veterinary Medicine 
(HFV-200), Food and Drug Administration, 7500 Standish Pl., Rockville, 
MD 20855, 301-594-5920, or FDA Advisory Committee Information Line, 1-
800-741-8138 (301-443-0572 in the Washington, DC area), code 12546. 
Please call the Information Line for up-to-date information on this 
meeting.
    Agenda: On May 13, 1997, the committee will discuss veterinary 
medical issues related to the quality standards for the manufacture of 
animal drugs, such as current good manufacturing practices. On May 14, 
1997, the committee will discuss topics concerned with the Animal Drug 
Use Clarification Act, specifically, the part of the regulation that 
permits extralabel use where a drug is clinically ineffective.
    Procedure: The meeting is open to the public. Interested persons 
may present data, information, or views, orally, or in writing, on 
issues pending before the committee. Written submissions may be made to 
the contact person by May 7, 1997. Those desiring to make formal 
presentations should notify the contact person before May 7, 1997, and 
submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of

[[Page 20191]]

proposed participants, and an indication of the approximate time 
requested to make their presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C., App. 2).

    Dated: April 21, 1997.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 97-10780 Filed 4-24-97; 8:45 am]
BILLING CODE 4160-01-F